PureTech Health (PRTC) Stock Forecast, Price Target & Predictions
PRTC Stock Forecast
PureTech Health stock forecast is as follows: an average price target of $57.00 (represents a 205.79% upside from PRTC’s last price of $18.64) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PRTC Price Target
PRTC Analyst Ratings
Buy
PureTech Health Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 25, 2022 | Edward Tenthoff | Piper Sandler | $44.00 | $30.50 | 44.26% | 136.05% |
Aug 09, 2022 | Leerink Partners | $70.00 | $27.52 | 154.36% | 275.54% | |
Jun 15, 2022 | Leerink Partners | $66.00 | $19.50 | 238.46% | 254.08% | |
Jun 14, 2022 | Edward Tenthoff | Piper Sandler | $37.00 | $19.50 | 89.74% | 98.50% |
PureTech Health Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $18.64 | $18.64 | $18.64 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 25, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Aug 09, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Jun 15, 2022 | SVB Leerink | Outperform | Outperform | Hold |
PureTech Health Financial Forecast
PureTech Health Revenue Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
---|---|---|---|---|
Revenue | - | - | - | - |
Avg Forecast | $286.53K | $287.26K | $7.50M | $6.00M |
High Forecast | $286.53K | $287.26K | $7.50M | $6.00M |
Low Forecast | $286.53K | $287.26K | $7.50M | $6.00M |
# Analysts | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - |
Forecast
PureTech Health EBITDA Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - |
Avg Forecast | $-57.30K | $-57.45K | $-1.50M | $-1.20M |
High Forecast | $-57.30K | $-57.45K | $-1.50M | $-1.20M |
Low Forecast | $-57.30K | $-57.45K | $-1.50M | $-1.20M |
Surprise % | - | - | - | - |
Forecast
PureTech Health Net Income Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - |
Avg Forecast | - | $415.65M | $-817.06M | $-876.38M |
High Forecast | - | $415.65M | $-817.06M | $-876.38M |
Low Forecast | - | $415.65M | $-817.06M | $-876.38M |
Surprise % | - | - | - | - |
Forecast
PureTech Health SG&A Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - |
Avg Forecast | $2.40M | $2.41M | $62.80M | $50.24M |
High Forecast | $2.40M | $2.41M | $62.80M | $50.24M |
Low Forecast | $2.40M | $2.41M | $62.80M | $50.24M |
Surprise % | - | - | - | - |
Forecast
PureTech Health EPS Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 |
EPS | - | - | - | - |
Avg Forecast | - | $1.54 | $-3.03 | $-3.25 |
High Forecast | - | $1.54 | $-3.03 | $-3.25 |
Low Forecast | - | $1.54 | $-3.03 | $-3.25 |
Surprise % | - | - | - | - |
Forecast
PureTech Health Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
ACRV | Acrivon Therapeutics | $5.55 | $22.50 | 305.41% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.54 | $6.00 | 289.61% | Buy |
PRTC | PureTech Health | $18.64 | $57.00 | 205.79% | Buy |
MLYS | Mineralys Therapeutics | $10.36 | $30.00 | 189.58% | Buy |
NUVB | Nuvation Bio | $2.42 | $7.00 | 189.26% | Buy |
OPT | Opthea | $5.07 | $14.00 | 176.13% | Buy |
JANX | Janux Therapeutics | $42.51 | $70.25 | 65.26% | Buy |
RZLT | Rezolute | $5.06 | $6.67 | 31.82% | Buy |